| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 188 | 2025 | 992 | 20.970 |
Why?
|
| Autoantibodies | 70 | 2022 | 479 | 7.400 |
Why?
|
| Autoimmunity | 31 | 2025 | 158 | 7.090 |
Why?
|
| Herpesvirus 4, Human | 23 | 2025 | 43 | 5.100 |
Why?
|
| Autoantigens | 45 | 2022 | 212 | 5.000 |
Why?
|
| B-Lymphocytes | 38 | 2025 | 285 | 3.990 |
Why?
|
| Antibodies, Bacterial | 18 | 2021 | 103 | 3.820 |
Why?
|
| Genetic Predisposition to Disease | 72 | 2025 | 671 | 3.800 |
Why?
|
| Epstein-Barr Virus Infections | 15 | 2025 | 28 | 3.790 |
Why?
|
| Lupus Nephritis | 22 | 2025 | 102 | 3.770 |
Why?
|
| Antibodies, Antinuclear | 27 | 2025 | 183 | 3.310 |
Why?
|
| Epitopes | 43 | 2022 | 185 | 3.310 |
Why?
|
| Humans | 287 | 2025 | 28585 | 3.230 |
Why?
|
| Antibodies, Viral | 20 | 2022 | 80 | 3.200 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 15 | 2025 | 20 | 2.960 |
Why?
|
| Sjogren's Syndrome | 19 | 2025 | 274 | 2.790 |
Why?
|
| Antigens, Bacterial | 16 | 2022 | 164 | 2.740 |
Why?
|
| Bacterial Toxins | 18 | 2022 | 269 | 2.690 |
Why?
|
| African Americans | 35 | 2020 | 352 | 2.570 |
Why?
|
| Polymorphism, Single Nucleotide | 60 | 2022 | 550 | 2.450 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 18 | 2009 | 41 | 2.450 |
Why?
|
| Female | 153 | 2025 | 15472 | 2.380 |
Why?
|
| Antibody Specificity | 17 | 2021 | 114 | 2.240 |
Why?
|
| Adult | 87 | 2025 | 7922 | 2.230 |
Why?
|
| Male | 128 | 2025 | 13772 | 2.170 |
Why?
|
| Middle Aged | 76 | 2025 | 7310 | 2.160 |
Why?
|
| Anthrax Vaccines | 10 | 2020 | 35 | 2.130 |
Why?
|
| Molecular Mimicry | 8 | 2021 | 30 | 2.050 |
Why?
|
| Arthritis, Rheumatoid | 10 | 2025 | 134 | 2.040 |
Why?
|
| Cytokines | 15 | 2024 | 448 | 1.890 |
Why?
|
| Case-Control Studies | 50 | 2025 | 732 | 1.870 |
Why?
|
| Autoimmune Diseases | 13 | 2022 | 166 | 1.840 |
Why?
|
| Immunoglobulin G | 22 | 2022 | 272 | 1.740 |
Why?
|
| Antibodies, Monoclonal | 18 | 2022 | 333 | 1.710 |
Why?
|
| Ribonucleoproteins | 24 | 2021 | 154 | 1.650 |
Why?
|
| Antibodies, Anticardiolipin | 5 | 2017 | 23 | 1.600 |
Why?
|
| Antibody Formation | 11 | 2022 | 77 | 1.530 |
Why?
|
| Anthrax | 11 | 2024 | 91 | 1.510 |
Why?
|
| Influenza Vaccines | 8 | 2016 | 51 | 1.450 |
Why?
|
| Antibodies, Neutralizing | 12 | 2022 | 73 | 1.420 |
Why?
|
| Bacillus anthracis | 11 | 2024 | 153 | 1.390 |
Why?
|
| Haplotypes | 38 | 2020 | 284 | 1.370 |
Why?
|
| Immunity, Humoral | 10 | 2021 | 47 | 1.340 |
Why?
|
| B-Cell Activating Factor | 7 | 2025 | 32 | 1.320 |
Why?
|
| Multiple Sclerosis | 6 | 2021 | 89 | 1.320 |
Why?
|
| snRNP Core Proteins | 18 | 2021 | 33 | 1.310 |
Why?
|
| Lymphocyte Activation | 9 | 2025 | 210 | 1.240 |
Why?
|
| Interferon-alpha | 12 | 2020 | 50 | 1.210 |
Why?
|
| Adaptive Immunity | 5 | 2019 | 38 | 1.180 |
Why?
|
| Signal Transduction | 11 | 2021 | 1455 | 1.150 |
Why?
|
| Rheumatic Diseases | 3 | 2022 | 33 | 1.130 |
Why?
|
| Biomarkers | 19 | 2022 | 770 | 1.110 |
Why?
|
| Monocytes | 7 | 2025 | 135 | 1.080 |
Why?
|
| T-Lymphocytes | 9 | 2021 | 285 | 1.060 |
Why?
|
| Risk Factors | 31 | 2022 | 2111 | 1.060 |
Why?
|
| Amino Acid Sequence | 29 | 2021 | 695 | 1.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 18 | 2020 | 257 | 1.050 |
Why?
|
| Animals | 57 | 2025 | 10583 | 1.010 |
Why?
|
| Peptide Fragments | 9 | 2011 | 202 | 1.000 |
Why?
|
| Young Adult | 24 | 2024 | 2804 | 0.980 |
Why?
|
| Interferon Type I | 5 | 2017 | 56 | 0.980 |
Why?
|
| Interleukin-10 | 6 | 2025 | 74 | 0.980 |
Why?
|
| Aged | 30 | 2025 | 5525 | 0.980 |
Why?
|
| Vitamin D Deficiency | 4 | 2016 | 31 | 0.970 |
Why?
|
| Antigens, Viral | 7 | 2019 | 24 | 0.950 |
Why?
|
| Rheumatology | 2 | 2023 | 18 | 0.950 |
Why?
|
| Severity of Illness Index | 15 | 2023 | 461 | 0.940 |
Why?
|
| Peptides | 10 | 2019 | 293 | 0.930 |
Why?
|
| Viral Proteins | 4 | 2021 | 63 | 0.920 |
Why?
|
| Immunization | 15 | 2021 | 121 | 0.900 |
Why?
|
| Viruses | 2 | 2021 | 20 | 0.890 |
Why?
|
| Immunity | 2 | 2014 | 26 | 0.860 |
Why?
|
| Extracellular Traps | 1 | 2024 | 9 | 0.850 |
Why?
|
| Alleles | 25 | 2021 | 354 | 0.840 |
Why?
|
| Ribosomal Proteins | 5 | 2016 | 20 | 0.820 |
Why?
|
| Interferon-gamma | 4 | 2019 | 107 | 0.820 |
Why?
|
| Cross Reactions | 12 | 2021 | 74 | 0.820 |
Why?
|
| Viral Matrix Proteins | 2 | 2021 | 6 | 0.810 |
Why?
|
| Inflammation Mediators | 5 | 2017 | 166 | 0.800 |
Why?
|
| Scleroderma, Systemic | 3 | 2025 | 29 | 0.800 |
Why?
|
| Gene Expression | 6 | 2020 | 417 | 0.800 |
Why?
|
| Genome-Wide Association Study | 17 | 2022 | 233 | 0.800 |
Why?
|
| Chemokine CXCL10 | 3 | 2020 | 22 | 0.790 |
Why?
|
| Molecular Sequence Data | 25 | 2012 | 1056 | 0.780 |
Why?
|
| Disease Progression | 12 | 2023 | 475 | 0.780 |
Why?
|
| Genotype | 32 | 2020 | 461 | 0.780 |
Why?
|
| DNA-Binding Proteins | 12 | 2020 | 490 | 0.760 |
Why?
|
| Adolescent | 23 | 2024 | 3165 | 0.760 |
Why?
|
| Herpesviridae Infections | 2 | 2019 | 17 | 0.750 |
Why?
|
| Epitope Mapping | 14 | 2022 | 38 | 0.730 |
Why?
|
| Vaccination | 8 | 2014 | 192 | 0.720 |
Why?
|
| Spliceosomes | 7 | 2004 | 11 | 0.720 |
Why?
|
| Kidney | 8 | 2025 | 286 | 0.720 |
Why?
|
| Steroids | 2 | 2019 | 58 | 0.710 |
Why?
|
| Connective Tissue Diseases | 3 | 2021 | 13 | 0.710 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 23 | 0.690 |
Why?
|
| Kidney Failure, Chronic | 3 | 2016 | 70 | 0.670 |
Why?
|
| Immunity, Innate | 5 | 2018 | 231 | 0.650 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.640 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2016 | 42 | 0.640 |
Why?
|
| Antirheumatic Agents | 4 | 2017 | 57 | 0.640 |
Why?
|
| Thrombosis | 2 | 2020 | 150 | 0.640 |
Why?
|
| Neutrophils | 5 | 2024 | 183 | 0.630 |
Why?
|
| United States | 18 | 2023 | 2201 | 0.630 |
Why?
|
| Macrophages | 6 | 2025 | 302 | 0.620 |
Why?
|
| Mice | 31 | 2025 | 4735 | 0.620 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.620 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.620 |
Why?
|
| Cohort Studies | 20 | 2022 | 893 | 0.620 |
Why?
|
| Immunophenotyping | 4 | 2025 | 61 | 0.610 |
Why?
|
| Virus Diseases | 4 | 2017 | 39 | 0.610 |
Why?
|
| Nuclear Family | 1 | 2019 | 12 | 0.610 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 74 | 0.610 |
Why?
|
| Serologic Tests | 2 | 2017 | 19 | 0.600 |
Why?
|
| Bacteria | 1 | 2021 | 286 | 0.590 |
Why?
|
| RNA, Small Cytoplasmic | 9 | 2013 | 63 | 0.590 |
Why?
|
| Disease Models, Animal | 8 | 2025 | 1494 | 0.580 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 2045 | 0.580 |
Why?
|
| Hydroxychloroquine | 4 | 2018 | 20 | 0.580 |
Why?
|
| Leukocytes | 2 | 2016 | 72 | 0.570 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 2018 | 50 | 0.560 |
Why?
|
| Epitopes, B-Lymphocyte | 5 | 2013 | 24 | 0.560 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2017 | 2 | 0.560 |
Why?
|
| Antibody-Producing Cells | 3 | 2018 | 15 | 0.560 |
Why?
|
| Immunosuppressive Agents | 5 | 2024 | 149 | 0.550 |
Why?
|
| Transcription Factors | 7 | 2020 | 523 | 0.550 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 128 | 0.540 |
Why?
|
| Genetic Loci | 8 | 2013 | 77 | 0.530 |
Why?
|
| Terminology as Topic | 1 | 2017 | 61 | 0.530 |
Why?
|
| Indians, North American | 5 | 2014 | 534 | 0.510 |
Why?
|
| STAT1 Transcription Factor | 5 | 2018 | 38 | 0.510 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 50 | 0.510 |
Why?
|
| Pneumococcal Vaccines | 2 | 2016 | 20 | 0.510 |
Why?
|
| Genetic Association Studies | 13 | 2018 | 115 | 0.500 |
Why?
|
| Immunoglobulin E | 1 | 2016 | 19 | 0.500 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2016 | 3 | 0.500 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2014 | 5 | 0.500 |
Why?
|
| B-Lymphocyte Subsets | 5 | 2019 | 30 | 0.500 |
Why?
|
| Interferon Regulatory Factors | 7 | 2016 | 58 | 0.490 |
Why?
|
| Linkage Disequilibrium | 14 | 2018 | 108 | 0.490 |
Why?
|
| Antitoxins | 2 | 2015 | 13 | 0.490 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 92 | 0.490 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2025 | 97 | 0.490 |
Why?
|
| Phenotype | 11 | 2023 | 682 | 0.480 |
Why?
|
| Gene Expression Regulation | 13 | 2021 | 633 | 0.480 |
Why?
|
| Immunoglobulin A | 4 | 2025 | 23 | 0.480 |
Why?
|
| Quantitative Trait Loci | 5 | 2018 | 53 | 0.470 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 67 | 0.470 |
Why?
|
| Allergy and Immunology | 1 | 2015 | 5 | 0.470 |
Why?
|
| Famous Persons | 1 | 2015 | 4 | 0.470 |
Why?
|
| Interleukins | 5 | 2020 | 112 | 0.460 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2025 | 83 | 0.460 |
Why?
|
| Polymorphism, Genetic | 4 | 2018 | 166 | 0.450 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2013 | 2 | 0.450 |
Why?
|
| HLA-DRB1 Chains | 3 | 2017 | 33 | 0.450 |
Why?
|
| Immunization, Secondary | 1 | 2014 | 10 | 0.440 |
Why?
|
| Time Factors | 13 | 2021 | 1600 | 0.440 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2014 | 2 | 0.440 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2025 | 111 | 0.440 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 17 | 0.440 |
Why?
|
| Bacterial Proteins | 5 | 2020 | 491 | 0.440 |
Why?
|
| Sex Factors | 8 | 2017 | 467 | 0.440 |
Why?
|
| Gene Frequency | 15 | 2020 | 185 | 0.430 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2015 | 40 | 0.430 |
Why?
|
| Ubiquitination | 1 | 2014 | 33 | 0.430 |
Why?
|
| Pneumonia | 1 | 2015 | 89 | 0.430 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2013 | 5 | 0.420 |
Why?
|
| Genetic Variation | 9 | 2019 | 245 | 0.410 |
Why?
|
| CD11b Antigen | 6 | 2016 | 42 | 0.410 |
Why?
|
| Logistic Models | 9 | 2019 | 409 | 0.400 |
Why?
|
| Centromere Protein B | 2 | 2016 | 3 | 0.390 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2017 | 247 | 0.390 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 23 | 0.380 |
Why?
|
| Genetic Linkage | 9 | 2018 | 95 | 0.380 |
Why?
|
| Furin | 1 | 2012 | 4 | 0.380 |
Why?
|
| Oligopeptides | 6 | 1999 | 97 | 0.370 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2012 | 26 | 0.370 |
Why?
|
| Chemokines | 2 | 2024 | 74 | 0.370 |
Why?
|
| Apoptosis | 5 | 2021 | 777 | 0.360 |
Why?
|
| Inflammation | 6 | 2024 | 642 | 0.360 |
Why?
|
| Vitamin D | 4 | 2022 | 51 | 0.360 |
Why?
|
| Mice, Inbred C57BL | 9 | 2025 | 1602 | 0.360 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 302 | 0.360 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 3 | 2021 | 16 | 0.360 |
Why?
|
| Vasculitis | 1 | 2011 | 13 | 0.350 |
Why?
|
| Immunodominant Epitopes | 1 | 2011 | 13 | 0.350 |
Why?
|
| Peroxidase | 1 | 2011 | 39 | 0.350 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 4 | 2013 | 16 | 0.340 |
Why?
|
| Nurses | 2 | 2021 | 13 | 0.340 |
Why?
|
| Immunologic Memory | 6 | 2020 | 58 | 0.340 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2010 | 1 | 0.340 |
Why?
|
| Myeloblastin | 1 | 2010 | 1 | 0.340 |
Why?
|
| Flow Cytometry | 8 | 2020 | 291 | 0.330 |
Why?
|
| Membrane Proteins | 5 | 2018 | 485 | 0.330 |
Why?
|
| Smoking Cessation | 1 | 2015 | 412 | 0.330 |
Why?
|
| Neutralization Tests | 7 | 2020 | 34 | 0.330 |
Why?
|
| DNA | 11 | 2025 | 375 | 0.320 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2025 | 117 | 0.320 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 3 | 2008 | 3 | 0.320 |
Why?
|
| Cytomegalovirus Infections | 3 | 2022 | 36 | 0.320 |
Why?
|
| Child | 12 | 2022 | 2271 | 0.320 |
Why?
|
| American Native Continental Ancestry Group | 4 | 2017 | 22 | 0.310 |
Why?
|
| Dendritic Cells | 5 | 2020 | 142 | 0.310 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2015 | 216 | 0.310 |
Why?
|
| Precision Medicine | 2 | 2022 | 76 | 0.310 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2014 | 78 | 0.300 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2018 | 163 | 0.300 |
Why?
|
| Antimalarials | 2 | 2019 | 25 | 0.300 |
Why?
|
| Up-Regulation | 2 | 2013 | 247 | 0.300 |
Why?
|
| Prognosis | 4 | 2016 | 807 | 0.300 |
Why?
|
| Plasma Cells | 3 | 2019 | 21 | 0.300 |
Why?
|
| Epigenesis, Genetic | 5 | 2021 | 148 | 0.300 |
Why?
|
| Osteopontin | 2 | 2025 | 10 | 0.300 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2020 | 82 | 0.290 |
Why?
|
| Prevalence | 9 | 2022 | 510 | 0.290 |
Why?
|
| Rabbits | 9 | 2008 | 277 | 0.290 |
Why?
|
| RNA-Binding Proteins | 3 | 2021 | 87 | 0.290 |
Why?
|
| Host-Pathogen Interactions | 3 | 2019 | 91 | 0.290 |
Why?
|
| Gene Regulatory Networks | 3 | 2020 | 78 | 0.280 |
Why?
|
| Environment | 3 | 2019 | 65 | 0.280 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 249 | 0.280 |
Why?
|
| Oklahoma | 8 | 2023 | 1038 | 0.280 |
Why?
|
| Models, Molecular | 7 | 2021 | 452 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2024 | 2402 | 0.270 |
Why?
|
| Interferons | 3 | 2020 | 70 | 0.270 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2020 | 59 | 0.270 |
Why?
|
| STAT4 Transcription Factor | 4 | 2018 | 23 | 0.270 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 994 | 0.270 |
Why?
|
| src-Family Kinases | 3 | 2014 | 71 | 0.270 |
Why?
|
| Self Tolerance | 2 | 2019 | 9 | 0.260 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 97 | 0.260 |
Why?
|
| Scleroderma, Limited | 1 | 2007 | 1 | 0.260 |
Why?
|
| Immunologic Factors | 1 | 2007 | 50 | 0.260 |
Why?
|
| Glucocorticoids | 3 | 2021 | 115 | 0.260 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 988 | 0.260 |
Why?
|
| Receptors, Antigen, B-Cell | 2 | 2025 | 35 | 0.260 |
Why?
|
| Th17 Cells | 2 | 2025 | 33 | 0.260 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2018 | 233 | 0.260 |
Why?
|
| Mice, Inbred BALB C | 6 | 2019 | 278 | 0.260 |
Why?
|
| Influenza, Human | 4 | 2011 | 92 | 0.250 |
Why?
|
| Cell Differentiation | 2 | 2019 | 419 | 0.250 |
Why?
|
| Military Personnel | 4 | 2014 | 49 | 0.250 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2007 | 79 | 0.240 |
Why?
|
| Lupus Erythematosus, Discoid | 3 | 2018 | 18 | 0.240 |
Why?
|
| Rheumatoid Factor | 4 | 2022 | 28 | 0.240 |
Why?
|
| Antigens | 3 | 2019 | 68 | 0.240 |
Why?
|
| Cellular Reprogramming | 1 | 2025 | 11 | 0.240 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2016 | 11 | 0.240 |
Why?
|
| Antigen-Presenting Cells | 1 | 2025 | 33 | 0.240 |
Why?
|
| Phagocytosis | 2 | 2019 | 80 | 0.240 |
Why?
|
| Osteoarthritis, Hip | 2 | 2016 | 12 | 0.240 |
Why?
|
| Myeloid Cells | 1 | 2025 | 27 | 0.230 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1026 | 0.230 |
Why?
|
| Immunoglobulin M | 4 | 2022 | 28 | 0.230 |
Why?
|
| Rituximab | 1 | 2025 | 64 | 0.230 |
Why?
|
| Gene Expression Profiling | 6 | 2025 | 453 | 0.230 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 404 | 0.230 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 3 | 2016 | 14 | 0.230 |
Why?
|
| Pulmonary Fibrosis | 1 | 2025 | 15 | 0.230 |
Why?
|
| Mice, Transgenic | 4 | 2021 | 509 | 0.230 |
Why?
|
| Bleomycin | 1 | 2025 | 11 | 0.230 |
Why?
|
| Pandemics | 2 | 2020 | 196 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 3 | 2019 | 154 | 0.220 |
Why?
|
| Antibody Affinity | 4 | 2015 | 13 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 147 | 0.220 |
Why?
|
| Fluorescent Antibody Technique | 6 | 2021 | 114 | 0.220 |
Why?
|
| Oxygen | 3 | 2021 | 234 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 389 | 0.210 |
Why?
|
| HeLa Cells | 6 | 2010 | 208 | 0.210 |
Why?
|
| Carrier Proteins | 2 | 2016 | 252 | 0.210 |
Why?
|
| Mycophenolic Acid | 1 | 2024 | 18 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2012 | 285 | 0.210 |
Why?
|
| Machine Learning | 1 | 2025 | 91 | 0.210 |
Why?
|
| Promoter Regions, Genetic | 5 | 2021 | 344 | 0.210 |
Why?
|
| Registries | 3 | 2017 | 393 | 0.210 |
Why?
|
| Chromosome Mapping | 6 | 2013 | 128 | 0.210 |
Why?
|
| Phosphoproteins | 2 | 2016 | 120 | 0.210 |
Why?
|
| Infectious Mononucleosis | 1 | 2003 | 2 | 0.200 |
Why?
|
| Protein Binding | 6 | 2015 | 664 | 0.200 |
Why?
|
| Family | 3 | 2013 | 98 | 0.200 |
Why?
|
| Cell Communication | 2 | 2021 | 68 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2025 | 125 | 0.200 |
Why?
|
| Chemokine CXCL13 | 2 | 2020 | 7 | 0.200 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2023 | 14 | 0.200 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 366 | 0.200 |
Why?
|
| Apolipoproteins | 2 | 2014 | 21 | 0.200 |
Why?
|
| Kidney Diseases | 2 | 2015 | 61 | 0.200 |
Why?
|
| Vaccines | 1 | 2023 | 35 | 0.200 |
Why?
|
| Seroepidemiologic Studies | 3 | 2012 | 10 | 0.200 |
Why?
|
| Lipoproteins, HDL | 2 | 2014 | 41 | 0.190 |
Why?
|
| Models, Immunological | 1 | 2002 | 22 | 0.190 |
Why?
|
| Salivary Glands | 2 | 2025 | 58 | 0.190 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2022 | 9 | 0.190 |
Why?
|
| Asian Americans | 5 | 2013 | 40 | 0.190 |
Why?
|
| Incidence | 4 | 2022 | 568 | 0.190 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2020 | 16 | 0.190 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2020 | 11 | 0.190 |
Why?
|
| RNA, Small Nuclear | 1 | 2002 | 5 | 0.190 |
Why?
|
| Risk Assessment | 4 | 2021 | 622 | 0.190 |
Why?
|
| Interleukin-16 | 1 | 2022 | 2 | 0.190 |
Why?
|
| Antigens, Surface | 3 | 2019 | 39 | 0.190 |
Why?
|
| NADPH Oxidases | 3 | 2025 | 69 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2024 | 1272 | 0.190 |
Why?
|
| White Matter | 1 | 2023 | 90 | 0.190 |
Why?
|
| Clostridium Infections | 2 | 2020 | 67 | 0.190 |
Why?
|
| Protein Conformation | 5 | 2021 | 257 | 0.190 |
Why?
|
| Genetic Load | 2 | 2023 | 6 | 0.190 |
Why?
|
| Capsid Proteins | 2 | 2022 | 12 | 0.190 |
Why?
|
| RNA, Messenger | 6 | 2021 | 667 | 0.180 |
Why?
|
| Sepsis | 2 | 2013 | 86 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2021 | 5 | 0.180 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 17 | 0.180 |
Why?
|
| Self Report | 1 | 2022 | 121 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 79 | 0.180 |
Why?
|
| Behcet Syndrome | 1 | 2021 | 4 | 0.180 |
Why?
|
| Environmental Exposure | 2 | 2014 | 49 | 0.180 |
Why?
|
| Arteriovenous Fistula | 1 | 2021 | 16 | 0.180 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2021 | 1 | 0.180 |
Why?
|
| Receptors, Interferon | 1 | 2021 | 13 | 0.180 |
Why?
|
| DNA Methylation | 4 | 2016 | 152 | 0.180 |
Why?
|
| Biological Products | 1 | 2022 | 66 | 0.170 |
Why?
|
| Enterococcus | 1 | 2021 | 19 | 0.170 |
Why?
|
| Women's Health | 1 | 2021 | 61 | 0.170 |
Why?
|
| ADAM Proteins | 2 | 2015 | 103 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2024 | 2612 | 0.170 |
Why?
|
| CD40 Antigens | 1 | 2021 | 14 | 0.170 |
Why?
|
| Complement C1q | 3 | 2013 | 13 | 0.170 |
Why?
|
| Cell Nucleus | 1 | 2021 | 138 | 0.170 |
Why?
|
| Cell Proliferation | 2 | 2021 | 817 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 33 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 16 | 0.170 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 22 | 0.170 |
Why?
|
| Complement System Proteins | 1 | 2020 | 24 | 0.170 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 3 | 0.160 |
Why?
|
| Chemokine CXCL9 | 1 | 2020 | 3 | 0.160 |
Why?
|
| Hypertension | 1 | 2023 | 309 | 0.160 |
Why?
|
| Interleukin-1alpha | 1 | 2020 | 7 | 0.160 |
Why?
|
| Smokers | 1 | 2021 | 128 | 0.160 |
Why?
|
| Lung | 2 | 2015 | 380 | 0.160 |
Why?
|
| Complement C4 | 1 | 2020 | 16 | 0.160 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2020 | 9 | 0.160 |
Why?
|
| Fibrinogen | 1 | 2020 | 50 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2010 | 34 | 0.160 |
Why?
|
| Complement C3 | 1 | 2020 | 21 | 0.160 |
Why?
|
| Intestines | 1 | 2021 | 118 | 0.160 |
Why?
|
| Cells, Cultured | 7 | 2019 | 1009 | 0.160 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 2 | 0.160 |
Why?
|
| Preliminary Data | 1 | 2020 | 4 | 0.160 |
Why?
|
| Complement Activation | 1 | 2020 | 27 | 0.160 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 24 | 0.160 |
Why?
|
| Blotting, Western | 5 | 2005 | 515 | 0.160 |
Why?
|
| Drug Industry | 1 | 2020 | 14 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 328 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 27 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2019 | 2 | 0.160 |
Why?
|
| Plasma Exchange | 1 | 2020 | 104 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2021 | 194 | 0.160 |
Why?
|
| Seroconversion | 1 | 2019 | 4 | 0.160 |
Why?
|
| Viral Load | 2 | 2012 | 32 | 0.160 |
Why?
|
| Interferon-beta | 2 | 2017 | 40 | 0.160 |
Why?
|
| Platelet Count | 1 | 2020 | 111 | 0.160 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 2 | 2017 | 11 | 0.160 |
Why?
|
| Mice, Inbred Strains | 4 | 2013 | 61 | 0.160 |
Why?
|
| Cytomegalovirus | 2 | 2017 | 22 | 0.160 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 76 | 0.160 |
Why?
|
| Algorithms | 3 | 2011 | 430 | 0.160 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 8 | 0.160 |
Why?
|
| Smoking | 2 | 2021 | 476 | 0.160 |
Why?
|
| Interleukin-12 Subunit p40 | 2 | 2016 | 8 | 0.150 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2019 | 18 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2020 | 114 | 0.150 |
Why?
|
| Patient Participation | 1 | 2020 | 56 | 0.150 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 34 | 0.150 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2021 | 19 | 0.150 |
Why?
|
| HEK293 Cells | 5 | 2021 | 188 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 135 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2020 | 128 | 0.150 |
Why?
|
| Organ Specificity | 1 | 2019 | 82 | 0.150 |
Why?
|
| Ultraviolet Rays | 2 | 2021 | 40 | 0.150 |
Why?
|
| HLA Antigens | 2 | 2017 | 61 | 0.150 |
Why?
|
| Neurovascular Coupling | 1 | 2021 | 154 | 0.150 |
Why?
|
| Patient Selection | 1 | 2019 | 149 | 0.150 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 14 | 0.150 |
Why?
|
| Major Histocompatibility Complex | 1 | 2018 | 28 | 0.150 |
Why?
|
| Receptors, Complement 3d | 2 | 2018 | 7 | 0.150 |
Why?
|
| Chromosomes, Human, X | 3 | 2016 | 38 | 0.150 |
Why?
|
| Bone Diseases, Developmental | 1 | 2018 | 6 | 0.150 |
Why?
|
| Serine Endopeptidases | 1 | 2018 | 19 | 0.140 |
Why?
|
| Peptidoglycan | 2 | 2024 | 47 | 0.140 |
Why?
|
| Prednisone | 3 | 2024 | 53 | 0.140 |
Why?
|
| Periodontitis | 1 | 2018 | 11 | 0.140 |
Why?
|
| Mutation | 7 | 2018 | 864 | 0.140 |
Why?
|
| Proprotein Convertases | 1 | 2018 | 12 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2019 | 127 | 0.140 |
Why?
|
| Decision Making | 1 | 2020 | 177 | 0.140 |
Why?
|
| beta Karyopherins | 2 | 2016 | 13 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 175 | 0.140 |
Why?
|
| Age Factors | 3 | 2016 | 734 | 0.140 |
Why?
|
| Models, Biological | 2 | 2019 | 468 | 0.140 |
Why?
|
| Immunoglobulins | 2 | 2014 | 34 | 0.140 |
Why?
|
| Pedigree | 8 | 2016 | 155 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2020 | 295 | 0.140 |
Why?
|
| Herpes Simplex | 2 | 2012 | 20 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 114 | 0.140 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 6 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 115 | 0.140 |
Why?
|
| Tumor Virus Infections | 1 | 1997 | 14 | 0.140 |
Why?
|
| United States Virgin Islands | 1 | 2017 | 4 | 0.140 |
Why?
|
| British Virgin Islands | 1 | 2017 | 4 | 0.140 |
Why?
|
| Puerto Rico | 1 | 2017 | 6 | 0.140 |
Why?
|
| Cognition | 1 | 2021 | 327 | 0.140 |
Why?
|
| Protein Transport | 1 | 2018 | 158 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2018 | 140 | 0.140 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 44 | 0.140 |
Why?
|
| Chromatin | 1 | 2018 | 76 | 0.140 |
Why?
|
| Child, Preschool | 4 | 2021 | 1167 | 0.140 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 3 | 2013 | 14 | 0.140 |
Why?
|
| Binding Sites | 4 | 2018 | 354 | 0.140 |
Why?
|
| Breast Feeding | 2 | 2017 | 98 | 0.140 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2017 | 9 | 0.130 |
Why?
|
| Protein Multimerization | 2 | 2021 | 57 | 0.130 |
Why?
|
| Antigens, Nuclear | 3 | 2013 | 22 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2017 | 20 | 0.130 |
Why?
|
| Isoelectric Point | 2 | 2010 | 7 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2017 | 15 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 301 | 0.130 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2016 | 7 | 0.130 |
Why?
|
| Stem Cell Factor | 1 | 2016 | 5 | 0.130 |
Why?
|
| Genome, Human | 3 | 2013 | 70 | 0.130 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2016 | 10 | 0.130 |
Why?
|
| Base Sequence | 4 | 2012 | 588 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2016 | 18 | 0.130 |
Why?
|
| Transcriptome | 3 | 2025 | 214 | 0.130 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2016 | 4 | 0.130 |
Why?
|
| Tumor Necrosis Factors | 1 | 2016 | 15 | 0.130 |
Why?
|
| Binding Sites, Antibody | 1 | 1996 | 14 | 0.130 |
Why?
|
| Interleukin-17 | 1 | 2016 | 52 | 0.130 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 3 | 0.130 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 10 | 0.120 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 11 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 480 | 0.120 |
Why?
|
| HLA-D Antigens | 1 | 2016 | 6 | 0.120 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 4 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 378 | 0.120 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2015 | 2 | 0.120 |
Why?
|
| Antigen-Antibody Complex | 1 | 2015 | 19 | 0.120 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 10 | 0.120 |
Why?
|
| Receptors, IgG | 2 | 2013 | 47 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2015 | 32 | 0.120 |
Why?
|
| Age of Onset | 4 | 2017 | 72 | 0.120 |
Why?
|
| HL-60 Cells | 2 | 2012 | 22 | 0.120 |
Why?
|
| Orthomyxoviridae | 1 | 2015 | 4 | 0.120 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2015 | 5 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2015 | 49 | 0.120 |
Why?
|
| Leptin | 1 | 2015 | 67 | 0.120 |
Why?
|
| Antibodies | 3 | 2011 | 124 | 0.120 |
Why?
|
| Epistasis, Genetic | 2 | 2012 | 24 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 19 | 0.110 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2015 | 7 | 0.110 |
Why?
|
| Splenomegaly | 1 | 2015 | 10 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2015 | 84 | 0.110 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2015 | 12 | 0.110 |
Why?
|
| Interviews as Topic | 1 | 2015 | 160 | 0.110 |
Why?
|
| Heart | 1 | 2016 | 224 | 0.110 |
Why?
|
| Cell Line | 3 | 2015 | 698 | 0.110 |
Why?
|
| Mice, Inbred A | 2 | 2012 | 14 | 0.110 |
Why?
|
| Industrial Waste | 1 | 2014 | 7 | 0.110 |
Why?
|
| Ribosomes | 1 | 2015 | 32 | 0.110 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2014 | 12 | 0.110 |
Why?
|
| Salivary Glands, Minor | 1 | 2014 | 21 | 0.110 |
Why?
|
| Hip Joint | 1 | 2014 | 19 | 0.110 |
Why?
|
| Neuromyelitis Optica | 1 | 2014 | 9 | 0.110 |
Why?
|
| Mumps | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tetanus | 1 | 2014 | 5 | 0.110 |
Why?
|
| Heart Rate | 1 | 2016 | 380 | 0.110 |
Why?
|
| Hepatitis B | 1 | 2014 | 13 | 0.110 |
Why?
|
| Uranium | 1 | 2014 | 27 | 0.110 |
Why?
|
| Interleukin-2 | 2 | 2011 | 35 | 0.110 |
Why?
|
| Whooping Cough | 1 | 2014 | 15 | 0.110 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 7 | 0.110 |
Why?
|
| Faculty, Medical | 1 | 2015 | 59 | 0.110 |
Why?
|
| fas Receptor | 1 | 2014 | 19 | 0.110 |
Why?
|
| Measles | 1 | 2014 | 7 | 0.110 |
Why?
|
| CD40 Ligand | 1 | 2014 | 13 | 0.110 |
Why?
|
| Child Day Care Centers | 1 | 2014 | 25 | 0.110 |
Why?
|
| Species Specificity | 4 | 2012 | 193 | 0.110 |
Why?
|
| Prolidase Deficiency | 1 | 2013 | 3 | 0.110 |
Why?
|
| Asia | 1 | 2013 | 20 | 0.110 |
Why?
|
| HLA-DR3 Antigen | 1 | 2013 | 10 | 0.110 |
Why?
|
| Estrogens | 1 | 2014 | 56 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2015 | 98 | 0.100 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 2 | 2025 | 3 | 0.100 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 13 | 0.100 |
Why?
|
| Alaska | 1 | 2013 | 41 | 0.100 |
Why?
|
| CHO Cells | 4 | 2020 | 96 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2018 | 270 | 0.100 |
Why?
|
| Motivation | 1 | 2015 | 213 | 0.100 |
Why?
|
| Amino Acids | 1 | 1994 | 85 | 0.100 |
Why?
|
| Hypotension, Orthostatic | 1 | 2013 | 8 | 0.100 |
Why?
|
| Herpesvirus 3, Human | 1 | 2013 | 12 | 0.100 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2013 | 10 | 0.100 |
Why?
|
| Antigenic Variation | 1 | 2013 | 3 | 0.100 |
Why?
|
| OX40 Ligand | 1 | 2013 | 16 | 0.100 |
Why?
|
| Herpes Zoster | 1 | 2013 | 20 | 0.100 |
Why?
|
| Takayasu Arteritis | 1 | 2013 | 5 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2013 | 23 | 0.100 |
Why?
|
| Proteinuria | 2 | 2024 | 14 | 0.100 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 55 | 0.100 |
Why?
|
| Arthritis, Juvenile | 1 | 2013 | 9 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 79 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 37 | 0.100 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2013 | 20 | 0.100 |
Why?
|
| Genes, MHC Class II | 1 | 2012 | 10 | 0.100 |
Why?
|
| Immunodiffusion | 1 | 2012 | 12 | 0.100 |
Why?
|
| Indians, South American | 1 | 2012 | 12 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 26 | 0.100 |
Why?
|
| Opsonin Proteins | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cricetulus | 3 | 2020 | 56 | 0.100 |
Why?
|
| Clone Cells | 1 | 2012 | 22 | 0.100 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2012 | 9 | 0.100 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2012 | 13 | 0.100 |
Why?
|
| Streptococcus pneumoniae | 1 | 2012 | 29 | 0.100 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 54 | 0.100 |
Why?
|
| Peptides, Cyclic | 1 | 2012 | 30 | 0.090 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 9 | 0.090 |
Why?
|
| DNA, Viral | 2 | 2006 | 63 | 0.090 |
Why?
|
| Egg Proteins | 1 | 2012 | 17 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2013 | 301 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 405 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 34 | 0.090 |
Why?
|
| Immunization, Passive | 1 | 2012 | 20 | 0.090 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2012 | 15 | 0.090 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2012 | 11 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 782 | 0.090 |
Why?
|
| Herpesvirus 1, Human | 3 | 2014 | 24 | 0.090 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 6 | 0.090 |
Why?
|
| Cardiolipins | 1 | 2012 | 12 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 426 | 0.090 |
Why?
|
| Serositis | 1 | 2011 | 2 | 0.090 |
Why?
|
| Blood Sedimentation | 1 | 2011 | 5 | 0.090 |
Why?
|
| Leukocyte Common Antigens | 2 | 2008 | 17 | 0.090 |
Why?
|
| Molecular Motor Proteins | 1 | 2011 | 13 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 59 | 0.090 |
Why?
|
| Lymphopenia | 1 | 2011 | 8 | 0.090 |
Why?
|
| c-Mer Tyrosine Kinase | 2 | 2024 | 13 | 0.090 |
Why?
|
| ADAMTS13 Protein | 2 | 2015 | 126 | 0.090 |
Why?
|
| Proteolysis | 1 | 2012 | 59 | 0.090 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 24 | 0.090 |
Why?
|
| Germinal Center | 2 | 2008 | 24 | 0.090 |
Why?
|
| Exanthema | 1 | 2011 | 14 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 69 | 0.090 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 11 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2008 | 20 | 0.090 |
Why?
|
| Models, Genetic | 4 | 2018 | 125 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 16 | 0.090 |
Why?
|
| Complement Factor H | 1 | 2011 | 14 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 3 | 2021 | 11 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 47 | 0.090 |
Why?
|
| Exodeoxyribonucleases | 1 | 2011 | 6 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2012 | 123 | 0.090 |
Why?
|
| Endpoint Determination | 1 | 2011 | 18 | 0.090 |
Why?
|
| Calcifediol | 1 | 2011 | 1 | 0.090 |
Why?
|
| Proteomics | 2 | 2024 | 192 | 0.090 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 19 | 0.090 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 31 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 56 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2016 | 78 | 0.080 |
Why?
|
| Introns | 3 | 2018 | 43 | 0.080 |
Why?
|
| Skin Physiological Phenomena | 1 | 2010 | 8 | 0.080 |
Why?
|
| Surface Properties | 1 | 2010 | 134 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 82 | 0.080 |
Why?
|
| Bioterrorism | 1 | 2010 | 28 | 0.080 |
Why?
|
| Genetic Markers | 4 | 2012 | 92 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 145 | 0.080 |
Why?
|
| Muscle, Striated | 1 | 2010 | 3 | 0.080 |
Why?
|
| Galectin 1 | 1 | 2010 | 3 | 0.080 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2010 | 45 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2021 | 415 | 0.080 |
Why?
|
| Cytosol | 1 | 2010 | 49 | 0.080 |
Why?
|
| Interleukin-21 Receptor alpha Subunit | 1 | 2009 | 4 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2016 | 236 | 0.080 |
Why?
|
| RNA | 2 | 2021 | 111 | 0.080 |
Why?
|
| Alternative Splicing | 2 | 2017 | 48 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2011 | 27 | 0.080 |
Why?
|
| Coculture Techniques | 2 | 2019 | 55 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 123 | 0.080 |
Why?
|
| Lymphopoiesis | 1 | 2008 | 22 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2008 | 15 | 0.070 |
Why?
|
| Bayes Theorem | 3 | 2015 | 100 | 0.070 |
Why?
|
| Capsid | 2 | 2001 | 12 | 0.070 |
Why?
|
| Biopsy | 2 | 2021 | 207 | 0.070 |
Why?
|
| Surface Plasmon Resonance | 2 | 2013 | 37 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 3 | 2015 | 284 | 0.070 |
Why?
|
| Cell Culture Techniques | 2 | 2019 | 117 | 0.070 |
Why?
|
| Trans-Activators | 1 | 2008 | 118 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 410 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2018 | 421 | 0.070 |
Why?
|
| Turkey | 2 | 2020 | 10 | 0.070 |
Why?
|
| Herpesvirus 2, Human | 2 | 2011 | 4 | 0.070 |
Why?
|
| Centromere Protein A | 1 | 2007 | 2 | 0.070 |
Why?
|
| Computational Biology | 2 | 2021 | 156 | 0.060 |
Why?
|
| Immunoprecipitation | 2 | 2018 | 68 | 0.060 |
Why?
|
| Virus Latency | 1 | 2006 | 9 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2019 | 21 | 0.060 |
Why?
|
| RNA Stability | 1 | 2006 | 28 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2006 | 38 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2004 | 133 | 0.060 |
Why?
|
| Family Health | 1 | 2006 | 71 | 0.060 |
Why?
|
| Complementarity Determining Regions | 1 | 2025 | 11 | 0.060 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2025 | 4 | 0.060 |
Why?
|
| T-Box Domain Proteins | 1 | 2025 | 9 | 0.060 |
Why?
|
| Linear Models | 2 | 2020 | 202 | 0.060 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2025 | 1 | 0.060 |
Why?
|
| 3T3 Cells | 2 | 2021 | 46 | 0.060 |
Why?
|
| Granzymes | 1 | 2025 | 3 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 611 | 0.060 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cell Separation | 2 | 2019 | 55 | 0.060 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2016 | 14 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 48 | 0.060 |
Why?
|
| Genotyping Techniques | 2 | 2016 | 21 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 376 | 0.060 |
Why?
|
| Forecasting | 1 | 2005 | 76 | 0.060 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2024 | 6 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 251 | 0.050 |
Why?
|
| Remission Induction | 1 | 2024 | 58 | 0.050 |
Why?
|
| Creatinine | 1 | 2024 | 59 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 133 | 0.050 |
Why?
|
| Aggression | 1 | 2024 | 26 | 0.050 |
Why?
|
| Europe | 2 | 2016 | 99 | 0.050 |
Why?
|
| Immune Sera | 2 | 1996 | 22 | 0.050 |
Why?
|
| Recurrence | 2 | 2015 | 325 | 0.050 |
Why?
|
| Cell Wall | 1 | 2024 | 67 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 75 | 0.050 |
Why?
|
| Apolipoprotein L1 | 2 | 2014 | 10 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2002 | 10 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2022 | 19 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2002 | 8 | 0.050 |
Why?
|
| Lod Score | 4 | 2002 | 36 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2002 | 13 | 0.050 |
Why?
|
| Mexico | 2 | 2016 | 91 | 0.050 |
Why?
|
| Cell Nucleolus | 1 | 2002 | 26 | 0.050 |
Why?
|
| Nephritis | 1 | 2002 | 10 | 0.050 |
Why?
|
| Spermine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 194 | 0.050 |
Why?
|
| Homozygote | 1 | 2022 | 36 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2013 | 191 | 0.050 |
Why?
|
| Ligands | 2 | 2020 | 178 | 0.050 |
Why?
|
| Acetyltransferases | 1 | 2022 | 36 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Aging | 1 | 2010 | 979 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2023 | 93 | 0.050 |
Why?
|
| Amino Acids, Basic | 1 | 2002 | 2 | 0.050 |
Why?
|
| Antibodies, Heterophile | 1 | 2022 | 3 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2002 | 62 | 0.050 |
Why?
|
| Exoribonucleases | 2 | 2019 | 20 | 0.050 |
Why?
|
| Models, Animal | 1 | 2002 | 130 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2021 | 23 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 53 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2021 | 32 | 0.050 |
Why?
|
| Phospholipids | 1 | 2021 | 76 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2021 | 57 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2001 | 39 | 0.040 |
Why?
|
| DNA, Intergenic | 1 | 2021 | 4 | 0.040 |
Why?
|
| Hematoma | 1 | 2021 | 26 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 4 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 210 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2021 | 101 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2002 | 222 | 0.040 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2021 | 16 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2014 | 862 | 0.040 |
Why?
|
| Middle Cerebral Artery | 1 | 2021 | 50 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 25 | 0.040 |
Why?
|
| Disulfides | 1 | 2021 | 34 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 15 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 32 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2021 | 130 | 0.040 |
Why?
|
| Memory, Short-Term | 1 | 2021 | 62 | 0.040 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 34 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 67 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2021 | 80 | 0.040 |
Why?
|
| CpG Islands | 1 | 2020 | 26 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 524 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2020 | 112 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2021 | 152 | 0.040 |
Why?
|
| Altruism | 1 | 2020 | 8 | 0.040 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 2 | 2011 | 24 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2021 | 221 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 200 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 157 | 0.040 |
Why?
|
| Culture | 1 | 2020 | 27 | 0.040 |
Why?
|
| Autophagy | 1 | 2020 | 74 | 0.040 |
Why?
|
| Temperature | 1 | 2021 | 213 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 199 | 0.040 |
Why?
|
| Polymers | 1 | 2021 | 117 | 0.040 |
Why?
|
| Genetics, Population | 2 | 2012 | 72 | 0.040 |
Why?
|
| Receptors, CXCR5 | 1 | 2019 | 3 | 0.040 |
Why?
|
| CD11c Antigen | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 36 | 0.040 |
Why?
|
| Swine | 2 | 2011 | 238 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 101 | 0.040 |
Why?
|
| Mucin-5B | 1 | 2019 | 1 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 6 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2020 | 88 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 58 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 6 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 17 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 39 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 90 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 38 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 75 | 0.040 |
Why?
|
| Telomerase | 1 | 2019 | 38 | 0.040 |
Why?
|
| Receptors, Vitronectin | 1 | 2019 | 4 | 0.040 |
Why?
|
| Protein S | 1 | 2019 | 26 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 23 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2019 | 23 | 0.040 |
Why?
|
| Ephrin-A5 | 1 | 2019 | 1 | 0.040 |
Why?
|
| Milk Proteins | 1 | 2019 | 19 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2019 | 22 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 49 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 54 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2019 | 63 | 0.040 |
Why?
|
| Proline | 1 | 1998 | 11 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 834 | 0.040 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2019 | 87 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 38 | 0.040 |
Why?
|
| Mannosephosphates | 1 | 2018 | 5 | 0.040 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2018 | 1 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 216 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 14 | 0.040 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2008 | 4 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 200 | 0.040 |
Why?
|
| Treponema denticola | 1 | 2018 | 6 | 0.040 |
Why?
|
| Porphyromonas gingivalis | 1 | 2018 | 7 | 0.040 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2008 | 10 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 131 | 0.040 |
Why?
|
| Golgi Apparatus | 1 | 2018 | 26 | 0.040 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2018 | 20 | 0.040 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2018 | 34 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2018 | 29 | 0.040 |
Why?
|
| Chondrocytes | 1 | 2018 | 30 | 0.040 |
Why?
|
| Glycosylation | 1 | 2018 | 70 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 80 | 0.040 |
Why?
|
| Lysosomes | 1 | 2018 | 56 | 0.040 |
Why?
|
| H-2 Antigens | 1 | 1998 | 14 | 0.030 |
Why?
|
| Vesicular stomatitis Indiana virus | 2 | 1995 | 8 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 134 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2008 | 68 | 0.030 |
Why?
|
| Computer Simulation | 1 | 1999 | 231 | 0.030 |
Why?
|
| Papio | 1 | 1998 | 81 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 13 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2017 | 22 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 38 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 118 | 0.030 |
Why?
|
| Symptom Flare Up | 1 | 2017 | 7 | 0.030 |
Why?
|
| California | 1 | 2017 | 70 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 66 | 0.030 |
Why?
|
| Collagen | 1 | 2018 | 156 | 0.030 |
Why?
|
| Cricetinae | 2 | 2013 | 131 | 0.030 |
Why?
|
| Hygiene | 1 | 2017 | 38 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2016 | 24 | 0.030 |
Why?
|
| Polymyositis | 1 | 1996 | 25 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2016 | 2 | 0.030 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2016 | 3 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2016 | 6 | 0.030 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2016 | 8 | 0.030 |
Why?
|
| Argentina | 1 | 2016 | 9 | 0.030 |
Why?
|
| Chile | 1 | 2016 | 9 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2016 | 35 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 16 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 19 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 194 | 0.030 |
Why?
|
| Hypergammaglobulinemia | 1 | 2016 | 7 | 0.030 |
Why?
|
| HLA-DQ Antigens | 1 | 2016 | 25 | 0.030 |
Why?
|
| Peru | 1 | 2016 | 31 | 0.030 |
Why?
|
| Tripartite Motif Proteins | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sulfur Radioisotopes | 1 | 2016 | 10 | 0.030 |
Why?
|
| P-Selectin | 1 | 1996 | 30 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 51 | 0.030 |
Why?
|
| Methionine | 1 | 2016 | 38 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 2016 | 38 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 72 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 19 | 0.030 |
Why?
|
| Viral Core Proteins | 1 | 1995 | 8 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1996 | 147 | 0.030 |
Why?
|
| Lip | 1 | 2014 | 10 | 0.030 |
Why?
|
| Ohio | 1 | 2014 | 9 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 60 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 50 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 1994 | 58 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 394 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 7 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 105 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 64 | 0.030 |
Why?
|
| Air Pollutants | 1 | 2014 | 18 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 78 | 0.030 |
Why?
|
| Molecular Weight | 2 | 1996 | 122 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 50 | 0.030 |
Why?
|
| Amish | 1 | 2013 | 3 | 0.030 |
Why?
|
| Propanolamines | 1 | 2013 | 16 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 31 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 23 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 22 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2013 | 28 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 28 | 0.030 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 12 | 0.030 |
Why?
|
| Viper Venoms | 1 | 2013 | 5 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 34 | 0.030 |
Why?
|
| Arterioles | 1 | 2013 | 61 | 0.030 |
Why?
|
| Microsatellite Repeats | 2 | 2004 | 59 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 58 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 66 | 0.030 |
Why?
|
| North America | 1 | 2013 | 41 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 15 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2013 | 29 | 0.030 |
Why?
|
| Receptors, CCR | 1 | 2013 | 4 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 13 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 63 | 0.030 |
Why?
|
| Glutathione Reductase | 1 | 2013 | 22 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2013 | 21 | 0.030 |
Why?
|
| Gram-Positive Bacteria | 1 | 2013 | 33 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 12 | 0.030 |
Why?
|
| Immune System | 1 | 2013 | 29 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2013 | 6 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2013 | 6 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2013 | 12 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2013 | 38 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 137 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 64 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 42 | 0.020 |
Why?
|
| Aorta | 1 | 2013 | 124 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2013 | 90 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 58 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1341 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 58 | 0.020 |
Why?
|
| Seasons | 1 | 2012 | 94 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 49 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2011 | 14 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 458 | 0.020 |
Why?
|
| Latin America | 1 | 2011 | 9 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2011 | 1 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 209 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2011 | 7 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2011 | 6 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2012 | 121 | 0.020 |
Why?
|
| Zoonoses | 1 | 2011 | 13 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 93 | 0.020 |
Why?
|
| New York | 1 | 2011 | 17 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 2011 | 6 | 0.020 |
Why?
|
| San Francisco | 1 | 2011 | 12 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 120 | 0.020 |
Why?
|
| Siblings | 1 | 2010 | 23 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 36 | 0.020 |
Why?
|
| Immunoblotting | 2 | 2005 | 124 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2010 | 9 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 1990 | 24 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 1587 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2010 | 20 | 0.020 |
Why?
|
| Protein Folding | 1 | 2009 | 47 | 0.020 |
Why?
|
| Korea | 1 | 2009 | 7 | 0.020 |
Why?
|
| Colombia | 1 | 2009 | 9 | 0.020 |
Why?
|
| Japan | 1 | 2009 | 23 | 0.020 |
Why?
|
| Immunoglobulin D | 1 | 2008 | 4 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2008 | 8 | 0.020 |
Why?
|
| Palatine Tonsil | 1 | 2008 | 10 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 32 | 0.020 |
Why?
|
| United Kingdom | 1 | 2009 | 77 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 93 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 534 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2008 | 119 | 0.020 |
Why?
|
| South Carolina | 1 | 2008 | 8 | 0.020 |
Why?
|
| Particulate Matter | 1 | 2008 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 19 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 42 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 78 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 95 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2008 | 52 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 144 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2008 | 259 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2010 | 361 | 0.020 |
Why?
|
| Intracellular Fluid | 1 | 2006 | 12 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2006 | 11 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 23 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2006 | 111 | 0.020 |
Why?
|
| Hemocyanins | 1 | 2005 | 7 | 0.010 |
Why?
|
| Aldehydes | 1 | 2005 | 55 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 126 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 169 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 163 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 391 | 0.010 |
Why?
|
| Cattle | 1 | 2005 | 388 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2002 | 30 | 0.010 |
Why?
|
| Crithidia | 1 | 2002 | 2 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Proteins | 1 | 2005 | 253 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 671 | 0.010 |
Why?
|
| Exosome Multienzyme Ribonuclease Complex | 1 | 1996 | 4 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 1996 | 6 | 0.010 |
Why?
|
| Syndrome | 1 | 1996 | 79 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 94 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 1996 | 78 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1995 | 47 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1996 | 338 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 48 | 0.010 |
Why?
|